Company CrisBio Technology

Algenex and Virbac sign international commercial licensing agreement for CrisBio¬ģ -based vaccine in major swine indication

Feb 22 2021

Algenex SL, a VC-backed biotechnology company delivering disruptive technologies for recombinant biologics production, and Virbac, the sixth largest animal health company worldwide, today announce that they have entered into an international licensing agreement for the development and commercialization of a CrisBio¬ģ-based vaccine in a major swine indication.

The vaccine will be developed jointly and manufactured using CrisBio¬ģ, Algenex‚Äô proprietary and patent protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors. CrisBio¬ģ represents a new paradigm in biologics production, offering a quick, linearly scalable solution to meet the global demand for recombinant protein production without significant capex investment. Algenex anticipates receiving European approval of the first veterinary vaccine produced using CrisBio¬ģ in 2021.

‚ÄúThis new collaboration with Virbac, one of the global leaders in animal health, is another important milestone for Algenex and a further validation of our unique CrisBio¬ģ technology and its potential to transform vaccine production in major indications across animal health‚ÄĚ, said Claudia Jim√©nez, CEO of Algenex.

‚ÄúWith this partnership, we will benefit from the experience of Algenex, and by providing a simple, scalable and cost-effective alternative to current bioreactor-based expression technologies on the market, we should be able to increase our footprint in the farm animals‚Äô vaccine market‚ÄĚ, said S√©bastien Huron, CEO, Virbac group.

Commercial and financial terms of the agreement were not disclosed. The agreement covers all global markets excluding Poland and Italy.

About Algenex

Algenex is a VC-backed biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate linear scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.

Algenex has successfully produced >200molecules in collaboration with public and private partners, including multiple international pharmaceutical companies, including VLPs, monomeric vaccines, diagnostic reagents, enzymes and growth factors.

About Virbac

Focusing on animal health, from the beginning. At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Everyday, we are committed to improving animals’ quality of life and to shaping together the future of animal health.

For more information, please visit www.virbac.com

For further information, please contact:

Algenex contact
Claudia Jiménez
CEO
cjimenez@algenex.com
Phone +34 91 452 49 41

Virbac contact
Manuela Rodriguez
Director of Investor relations
manuela.rodriguez@virbac.com
Phone +33 (0) 622 52 42 55

Company Technology

We participate in Bio‚ā¨quity Forum (May 17-19, 2021)

Feb 12 2021

Bio‚ā¨quity is¬† the most important investor conference for life¬†science in Europe and and we have been selected to present our innovative technology to the world.

Schedule a partnering meeting with us to learn how we can boost your projects: https://conferences.biocentury.com/bioequity-europe/presenting-companies

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com.

Más información:

Comunicación Algenex

Mónica Bernardo
mbernardo@agenciacomma.com
Móvil + 34 610 54 40 90

Rosa Matías
rmatias@agenciacomma.com
Móvil +34 676 96 07 69

Company Technology

Algenex selected as a finalist in Innovation Showcase

Feb 10 2021

We have been selected to present our innovative technology in Animal Health Innovation Europe (February 22-23, 2021), the sector’s premier investment forum in Europe showcasing the most exciting innovators companies in animal health and nutrition.

Schedule a partnering meeting with us to learn how we can boost your projects. https://www.kisacoresearch.com/events/ah-europe-2021#showcase

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com.

Más información:

Comunicación Algenex

Mónica Bernardo
mbernardo@agenciacomma.com
Móvil + 34 610 54 40 90

Rosa Matías
rmatias@agenciacomma.com
Móvil +34 676 96 07 69

Company CrisBio Technology

Algenex inaugura su nueva planta de fabricación de vacunas en Tres Cantos con capacidad de producción de hasta 100 millones de dosis vacunales

Sep 24 2020

El acto ha contado con la presencia de Pedro Duque, ministro de Ciencia e Innovación.

La compa√Ī√≠a, especializada en productos biotecnol√≥gicos, ampl√≠a su capacidad de producci√≥n y se adentra en el desarrollo de productos para la salud humana.

CrisBio¬ģ, la tecnolog√≠a exclusiva de Algenex, permitir√° la producci√≥n de vacunas de forma eficiente,r√°pida y econ√≥mica.

La compa√Ī√≠a biotecnol√≥gica espa√Īola Algenex ha inaugurado hoy, en Tres Cantos, su nueva planta de fabricaci√≥n dedicada al desarrollo de vacunas y otros productos biotecnol√≥gicos, a la que ha acudido el ministro de Ciencia e Innovaci√≥n, Pedro Duque. Tambi√©n ha contado con la presencia del vicepresidente de la Comunidad de Madrid, Ignacio Aguado, y del alcalde de Tres Cantos, Jes√ļs Moreno, adem√°s de destacados representantes del sector biotecnol√≥gico espa√Īol.

Con la nueva planta de producción, Algenex tiene la capacidad inicial de fabricar 50 millones de dosis vacunales que podría llegar a los 100 millones en un corto espacio de tiempo y con una inversión mínima. El sistema de producción de Algenex se puede aplicar a cualquier vacuna basada en proteínas. En el caso de la COVID-19 suponen aproximadamente el 40% de las candidatas actualmente en desarrollo.

Las nuevas instalaciones permitir√°n a la compa√Ī√≠a consolidarse en el √°mbito de las vacunas veterinarias, as√≠ como avanzar en el uso de su tecnolog√≠a exclusiva CrisBio¬ģ para el desarrollo de productos espec√≠ficos para la salud humana, tales como vacunas de gripe o un candidato a vacuna contra el SARS-CoV-2 en el que ya est√°n trabajando, as√≠ como ant√≠genos destinados a los tests diagn√≥sticos para la detecci√≥n de anticuerpos, entre otros.

En el acto inaugural, el ministro de Ciencia e Innovaci√≥n, Pedro Duque, ha destacado que Algenex surge en 2005 de una spin-off de un organismo p√ļblico de investigaci√≥n, el Instituto Nacional de Investigaci√≥n y Tecnolog√≠a Agraria y Alimentaria, y desde el inicio ha contado con financiaci√≥n del CDTI, por lo que es un claro caso de √©xito del sistema espa√Īol de ciencia, tecnolog√≠a e innovaci√≥n. El ministro tambi√©n ha resaltado el papel central de la investigaci√≥n y la innovaci√≥n para acabar con esta pandemia y para asegurar la recuperaci√≥n sostenible y el futuro de las siguientes generaciones.

Por su parte, la directora general de Algenex, Claudia Jim√©nez, ha explicado que: ‚ÄúEn solo 5 meses y con una inversi√≥n de menos de 2 millones de euros, hemos puesto en marcha una planta con capacidad de aportar soluciones a la industria farmac√©utica en t√©rminos de escalabilidad, versatilidad, tiempo de desarrollo y costes reducidos que permite globalizar el uso de productos biotecnol√≥gicos‚ÄĚ.

Con resultados demostrados de eficiencia productiva y eficacia protectiva en una vacuna frente a una variante de influenza aviar, una enfermedad zoon√≥tica que podr√≠a volverse pand√©mica, Claudia Jim√©nez ha puesto a disposici√≥n de las autoridades sanitarias ‚Äďdurante el acto de inauguraci√≥n‚Äď la capacidad de Algenex, su tecnolog√≠a y el compromiso para luchar contra las enfermedades infecciosas, incluida la pandemia de la COVID-19 que actualmente estamos viviendo.

Escalabilidad casi ilimitada

Algenex es una compa√Ī√≠a 100% espa√Īola especializada en la fabricaci√≥n de vacunas y otros productos biotecnol√≥gicos a partir del uso de cris√°lidas que act√ļan como biorreactores naturales. Se trata de una tecnolog√≠a simple, eficiente y extremadamente segura, que permite un desarrollo r√°pido y un escalado industrial productivo lineal y pr√°cticamente ilimitado, a costes muy inferiores a los empleados en los sistemas de fabricaci√≥n tradicional. Dependiendo del ant√≠geno y de la dosis de inmunizaci√≥n establecida, una cris√°lida infectada puede producir entre 10 y 80 dosis vacunales o suficiente ant√≠geno para producir miles de kits diagn√≥sticos.

Para el doctor Jos√© Escribano, director cient√≠fico y fundador de Algenex, ‚Äúla compa√Ī√≠a ha recorrido un largo camino para optimizar la fabricaci√≥n de productos biotecnol√≥gicos utilizando un organismo vivo y desarrollar todos los procedimientos industriales que hacen que CrisBio¬ģ pueda significar un antes y un despu√©s en la producci√≥n de vacunas, mol√©culas terap√©uticas o reactivos diagn√≥sticos‚ÄĚ.

El nuevo edificio consta de cerca de 900 metros cuadrados, la mayor parte dedicada al laboratorio de biolog√≠a molecular, la producci√≥n de cris√°lidas y a la obtenci√≥n mediante procesos robotizados de las diferentes mol√©culas. ‚ÄúLa nueva planta cuenta con todos los elementos que nuestros cient√≠ficos y t√©cnicos necesitan para el desarrollo y la innovaci√≥n, en un ambiente donde prima la tecnolog√≠a y la creatividad, tal y como corresponde a una empresa como Algenex. Es dif√≠cil imaginar una plataforma m√°s vers√°til, simple y econ√≥mica de producir productos biol√≥gicos complejos basados en prote√≠nas‚ÄĚ, a√Īade Jos√© Escribano.

Tecnología disruptiva y patentada

CrisBio¬ģ es una tecnolog√≠a disruptiva y patentada dise√Īada para producir productos biotecnol√≥gicos basados en prote√≠nas recombinantes. Para ello utiliza las cris√°lidas de un lepid√≥ptero, la trichoplusiani, que act√ļa como un biorreactor natural tras ser inoculado, de forma robotizada,con vectores viralesmodificados gen√©ticamente. El virus coloniza las c√©lulas vivas del insecto y √©stas comienzan a producir la prote√≠na deseada sin necesidad de medios artificiales ni manipulaci√≥n alguna.

Algenex cuenta con una amplia experiencia en el desarrollo de vacunas. La primera vacuna producida en CrisBio¬ģest√° actualmente en proceso de validaci√≥n por la Agencia Europea del Medicamento (EMA, por sus siglas en ingl√©s). Asimismo, cuenta con otras vacunas en desarrollo contra enfermedades v√≠ricas para varias especies en distintas fases de desarrollo, con capacidad de llegar al mercado en los pr√≥ximos a√Īos.

Hasta ahora, Algenex había utilizado esta tecnología para la fabricación de productos veterinarios. En la actualidad, están trabajando en el desarrollo de un prototipo de vacuna contra el SARS-CoV-2 y de prueba diagnóstica para la detección de anticuerpos en pacientes para los que han recibido una subvención del CDTI de 470.000 euros.

Descargar

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.

To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com.

Más información:

Comunicación Algenex

Mónica Bernardo
mbernardo@agenciacomma.com
Móvil + 34 610 54 40 90

Rosa Matías
rmatias@agenciacomma.com
Móvil +34 676 96 07 69

CrisBio Company

Algenex raises ‚ā¨7.4 million in financing round

Sep 13 2020

Algenex ¬†announces that it has secured investment of ‚ā¨7.4 million in a private financing round co-funded by new investor Columbus Venture Partners and existing investors.

Columbus Venture Partners is a leading Investment Management company focused on innovative early-stage and high-growth opportunities in the Spanish life science industry. Algenex will continue to be controlled by funds advised by Cleon Capital and Vita Advisory, who acquired a majority stake in 2018.

The new funds will be used to support the future development of Algenex‚Äô proprietary and patent protected CrisBio¬ģ technology, including the European approval of the first veterinary vaccine produced using this technology, currently anticipated in H1 2021. The funds will also be used to strengthen Algenex‚Äô new GMP production facilities and reinforce its pipeline of human vaccines. CrisBio¬ģ is Algenex‚Äô Baculovirus vector-mediated expression platform, which is used to produce biotechnology products for the development of human and veterinary vaccines and other applications. By harnessing the power of insects to act as natural single-use bioreactors, CrisBio¬ģ is a versatile and robust alternative to current bioreactor-based expression technologies, offering benefits that include linear scalability, reduced production costs and increased productivity reaching gram per litre yields.¬†Dami√° Tormo, Managing Partner and co-founder of Columbus Venture Partners, will join the Board of Algenex.

Potential to revolutionize vaccine production

‚ÄúAlgenex excels in the complex area of recombinant protein production and its unique CrisBio¬ģ platform has the potential to revolutionize vaccine production in human health,‚ÄĚ said Dami√° Tormo. ‚ÄúThe global COVID-19 pandemic has served to highlight the urgent need for faster, more economical methods of vaccine production and Algenex approach provides a more efficient, simple, scalable and cost-effective alternative to current bioreactor-based expression technologies on the market. We look forward to partnering with Cleon Capital, Vita Advisory and Algenex¬ī management team to support the Company as it continues to expand its proven capabilities into human health.‚ÄĚ

‚ÄúThis new financing is an important milestone for Algenex as we seek to further expand our proprietary CrisBio¬ģ platform technology in human health,‚ÄĚ said Claudia Jim√©nez, CEO of Algenex. ‚ÄúRaising these new funds during the global COVID-19 pandemic with the support of such an experienced new investor, alongside our existing shareholders, is a further validation of the potential of Algenex‚Äô technology and strategy and will enable us to fully exploit CrisBio¬ģ‚Äôs potential in the production of valuable proteins.‚ÄĚ

Nicola Zambon, Managing Partner and Founder of Cleon Capital said: ‚ÄúWe are very pleased with the progress made by Algenex and the management team since the initial investment in 2018. As the company enters into the next stage of development, we are excited by the prospect of partnering with Columbus to continue, jointly with management, to create significant value for our investors and shareholders‚ÄĚ.

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

CrisBio Company

Algenex cierra nueva ronda de financiación por 7,4 millones para afrontar sus nuevos proyectos en salud humana

Sep 08 2020

La Ronda ha sido liderada por MasterLux, socio mayoritario de Algenex desde 2018. Columbus Venture Partners se incorpora al grupo de inversores de la biotecnol√≥gica espa√Īola.

La compa√Ī√≠a biotecnol√≥gica Algenex ha cerrado una ronda de financiaci√≥n privada por valor de 7,4 millones de eurosliderada por MasterLux, inversor asesorado por Cleon Capital y Vita Advisory. Esta Ronda tambi√©n ha supuesto la entrada en el accionariado de Columbus Life Science Fund II, fondo liderado por la gestora Columbus Venture Partners, centrada en oportunidades innovadoras en fase inicial y de alto crecimiento en el sector biotecnol√≥gico espa√Īol.

Los nuevos recursos se destinar√°n a apoyar el desarrollo de la tecnolog√≠a propia y patentada de Algenex, CrisBio¬ģ, para su aplicaci√≥n aproyectos de salud humana y reforzar su cartera de vacunas veterinarias, la primera de las cuales se encuentra en proceso de registro por parte de la Agencia Europea del Medicamento. Otra parte ir√° destinada a reforzar las nuevas instalaciones de producci√≥n en Tres Cantos que la firma inaugurar√° oficialmente en Septiembre y que podr√≠an utilizarse para producir productos biotecnol√≥gicos frente a pandemias como la ocasionada por el coronavirus.

CrisBio¬ģ es la plataforma de expresi√≥n devectores de baculovirus de Algenex usada para producir productos biotecnol√≥gicos parael desarrollo de vacunas humanas y veterinarias, entre otras aplicaciones. Al aprovechar el poder de las cris√°lidas para actuar como biorreactores naturales, CrisBio¬ģ es una alternativa a las tecnolog√≠as de producci√≥n actuales basadas en biorreactores industriales, ya que ofrece beneficios que incluyen escalabilidad lineal, costes de producci√≥n reducidos y mayor productividad.

Claudia Jim√©nez, CEO de Algenex, subraya que: ‚ÄúEsta nueva financiaci√≥n es un hito importante para Algenex, ya que buscamos expandir a√ļn m√°s nuestra tecnolog√≠a CrisBio¬ģ en salud humana. Cerrar esta nueva ronda durante la pandemia global de COVID-19, con el apoyo de nuestros accionistas y un nuevo inversor tan experimentado, es una validaci√≥n m√°s del potencial de la tecnolog√≠a y la estrategia de Algenex y nos permitir√° desarrollar todo el potencial de CrisBio¬ģ en la producci√≥n de prote√≠nas valiosas”.

En opini√≥n de Dami√° Tormo, socio director y cofundador de Columbus Venture Partners, ‚ÄúAlgenex y su plataforma √ļnica CrisBio¬ģ tiene el potencial de revolucionar la producci√≥n de vacunas en la salud humana‚ÄĚ. Tormo, que se incorporar√° al Consejo de Algenex, considera que: ‚ÄúLa pandemia mundial de COVID-19 ha servido para resaltar la necesidad urgente de m√©todos m√°s r√°pidos y econ√≥micos de producci√≥n de vacunas. El enfoque de Algenex proporciona una alternativa m√°s eficiente, simple, escalable y rentable a las tecnolog√≠as de expresi√≥n actuales basadas en biorreactores. Esperamos colaborar con los socios actualesy el equipo directivode Algenex para apoyar a la compa√Ī√≠a en supenetraci√≥nen salud humana‚ÄĚ.

‚ÄúEstamos muy satisfechos con el progreso logrado por Algenex y el equipo de direcci√≥n desde la inversi√≥n inicial en 2018‚ÄĚ, a√Īade Nicola Zambon, socio gerente y fundador de Cleon Capital. ‚ÄúEstamos entusiasmados con la perspectiva de asociarnos con Columbus para continuar apoyando el desarrollo de Algenex, creando valor para nuestros inversores y accionistas‚ÄĚ, a√Īade.

Download

Sobre Algenex

Algenex es una compa√Ī√≠a privada de biotecnolog√≠a que desarrolla tecnolog√≠as disruptivas basadas en baculovirus para la producci√≥n de productos biol√≥gicos recombinantes. Las dos primeras plataformas de Algenex, TopBac¬ģ y CrisBio¬ģ, se basan en sistemas de expresi√≥n de baculovirus y han demostrado su capacidad para transformar la producci√≥n de prote√≠nas recombinantes a trav√©s de un proceso que proporciona escalabilidad casi ilimitada e inmediata de fabricaci√≥n, flexibilidad de producci√≥n, simplicidad y versatilidad de elevada rentabilidad.

Algenex ha desarrollado ya varios productos para salud animal, incluyendo la primera vacuna producida en su tecnolog√≠a CrisBio¬ģ, que est√° siendo evaluada actualmente por la Agencia Europea del Medicamento para su posible aprobaci√≥n en el primer semestre del 2021. Recientemente la compa√Ī√≠a empez√≥ su incursi√≥n en salud humana, con el objetivo de capitalizar las ventajas de CrisBio¬ģen la producci√≥n de vacunas y otros productos farmac√©uticos de gran necesidad.

Más información en Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Company CrisBio

Algenex obtiene 470.000 euros del CDTI para desarrollar productos para el control y la prevención del COVID-19

Aug 07 2020

CrisBio¬ģ, la disruptiva tecnolog√≠a de Algenex que utiliza insectos como biorreactores naturales, puede ser crucial en la fabricaci√≥n r√°pida, escalable y a bajo coste de la vacuna contra la COVID-19.

Tras el préstamo concedido en Mayo, esta es la segunda financiación que obtiene Algenex de este organismo para la lucha contra la COVID-19, al contar con uno de los proyectos para luchar contra la pandemia mejor valorado.

La compa√Ī√≠a biotecnol√≥gica espa√Īola Algenex ha obtenido una subvenci√≥n de 470.840 euros del CDTI, dependiente del Ministerio de Ciencia e Innovaci√≥n, para el desarrollo de distintos productos encaminados a luchar contra la actual pandemia de coronavirus. Esta financiaci√≥n permitir√° a la compa√Ī√≠a incrementar los trabajos que ya ha iniciado en el desarrollo de un candidato a vacuna contra el SARS-CoV-2, as√≠ como de test diagn√≥sticos para la detecci√≥n de anticuerpos.

El proyecto de Algenex: ‚ÄėDesarrollo integral para el control y la prevenci√≥n de la COVID-19‚Äô ha obtenido esta subvenci√≥n al ser uno de los mejor valorados de todos los que se han presentado a esta convocatoria del CDTI, y que le permitir√° ampliar el desarrollo de productos contra la COVID-19 que ya tienen iniciados.

Virginia Gonz√°lez, directora financiera de Algenex, ha destacado que la validaci√≥n del proyecto por el CDTI‚Äú supone una financiaci√≥n importante para una compa√Ī√≠a espa√Īola como la nuestra que cuenta con una tecnolog√≠a muy prometedora que permite escalar linealmente y de forma casi ilimitada la producci√≥n de vacunas; un hecho que ser√° cr√≠tico a la hora de garantizar la producci√≥n industrial de la futura vacuna contra la COVID-19 con el objetivo de poder abastecer a toda la poblaci√≥n mundial‚ÄĚ.

La tecnolog√≠a CrisBio¬ģ

Algenex, con sede en la Comunidad de Madrid, cuenta con una tecnolog√≠a disruptiva y patentada para producir productos biotecnol√≥gicos basados en prote√≠nas recombinantes denominada CrisBio¬ģ. Esta tecnolog√≠a utiliza insectos como biorreactores naturales, mediante la inoculaci√≥n robotizada de virus vectores baculovirus modificados gen√©ticamente, en las cris√°lidas de un lepid√≥ptero, la trichoplusia ni. El virus coloniza las c√©lulas vivas del insecto y √©stas comienzan a producir la prote√≠na deseada.

CrisBio¬ģ permite la producci√≥n de prote√≠nas para vacunas, anticuerpos y otros productos biotecnol√≥gicos de forma r√°pida y con un escalado industrial lineal y pr√°cticamente ilimitado; con unos costes m√≠nimos frente a los requeridos en factor√≠as tradicionales basadas en biorreactores, lo que permite el acceso global a productos biotecnol√≥gicos.

En diciembre del 2019, Algenex obtuvo datos positivos de una prueba de concepto realizada con una variante de gripe aviar con potencial de constituir una zoonosis que podr√≠a volverse pand√©mica. La compa√Ī√≠a demostr√≥ su capacidad de fabricar un candidato a vacuna en solo dos meses y mostr√≥ la funcionalidad y la plena seguridad de esta vacuna en modelos animales. Estos datos han servido para allanar el camino en salud humana, acometiendo proyectos de gran envergadura como el que est√° ahora financiando el CDTI. El pasado mes dejulio, Algenex traslad√≥ su sede desde el Parque Cient√≠fico y Tecnol√≥gico de la Universidad Polit√©cnica de Madrid,en Pozuelo de Alarc√≥n, a la localidad de Tres Cantos. En sus nuevas instalaciones Algenex cuenta con suficiente capacidad para producir ant√≠genos para la formulaci√≥n de hasta 100 millones de dosis vacunales al mes.

Descargar

Sobre Algenex

Algenex es una compa√Ī√≠a privada de biotecnolog√≠a que desarrolla tecnolog√≠as disruptivas basadas en baculovirus para la producci√≥n de productos biol√≥gicos recombinantes. Las dos primeras plataformas de Algenex, TopBac¬ģ y CrisBio¬ģ, se basan en sistemas de expresi√≥n de baculovirus y han demostrado su capacidad para transformar la producci√≥n de prote√≠nas recombinantes a trav√©s de un proceso que proporciona escalabilidad casi ilimitada e inmediata de fabricaci√≥n, flexibilidad de producci√≥n, simplicidad y versatilidad de elevada rentabilidad.

Algenex ha desarrollado ya varios productos para salud animal, incluyendo la primera vacuna producida en su tecnolog√≠a CrisBio¬ģ, que est√° siendo evaluada actualmente por la Agencia Europea del Medicamento para su posible aprobaci√≥n en el primer semestre del 2021. Recientemente la compa√Ī√≠a empez√≥ su incursi√≥n en salud humana, con el objetivo de capitalizar las ventajas de CrisBio¬ģ en la producci√≥n de vacunas y otros productos farmac√©uticos de gran necesidad.

Para más información, visite Algenex.com.

Más información:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Company CrisBio

Algenex and Global DX announce positive evaluation of Herdscreen¬ģ ASFV antibody test for African Swine Fever

Jul 21 2020

Analysis of this new rapid test at the ‚ÄčEuropean Union Reference Laboratory for African Swine Fever ‚Äč(CISA-INIA) shows 100% specificity and higher sensitivity than a commercial ELISA test for the detection of specific antibodies in field and experimental samples frominfected animals.

This new pen-side diagnostic test for African Swine Fever will be commercially availablein 2020. Discussions are ongoing with distributors in various territories.

Algenex SL, a private biotechnology company delivering disruptive technologies for recombinant biologics production, and Global DX Ltd., a company dedicated to improving the quality of animal care by facilitating accurate diagnosis for veterinarians worldwide, today announce results of a positive evaluation of the Herdscreen¬ģ ASFV Antibody Test.

The Herdscreen¬ģ ASFV Test is a point-of-care rapid diagnostic test to identify pigs who have been exposed to the African Swine Fever Virus (ASFV). It uses a carefully selected ASFV protein, which confers high sensitivity to the new test. The recombinant version of this antigen is produced through CrisBio¬ģ technology, Algenex‚Äô proprietary and patent protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors. The test is simple and easy to use and does not require complex technical training or sophisticated equipment.

Analysis conducted at Centro de Investigaci√≥n en Sanidad Animal (CISA-INIA) as a European Union Reference laboratory for African swine fever (EURL-ASF), in a validation study using 282 serum and blood samples from ASFV positive animals, showed the test to have analytical specificity of 100% and analytical sensitivity of 86%. Importantly, the sensitivity was greater than that shown by a commercial ELISA test. The Herdscreen¬ģ ASFV Test has been considered appropriate as a front-line diagnostic test for African Swine Fever (ASF) in field conditions for both serum and blood samples.

‚ÄúRapid detection of infected animals, as in any other infectious disease, is essential to avoid and mitigate the global dissemination of this dangerous virus, and helps sanitary authorities take rapid decisions when an infection is determined,‚ÄĚ said Dr. Jos√© Escribano, founder and CSO of Algenex and one of the world leading experts on ASF.

‚ÄúOur collaboration with Algenex, combining their expertise in protein expression and deep understanding of ASFV and our experience in developing best-in-class rapid diagnostic tests has resulted in a much needed diagnostic product for the simple and accurate detection of ASFV-infected pigs. We look forward to bringing this rapid test to the market as soon as possible,‚ÄĚ said Andrew Shepherd, Founder and CEO of Global DX.

African Swine Fever is a severe viral disease for which there is currently no available vaccine. It affects domestic pigs and wild boars and causes high mortality, approaching 100% in less than 10 days in acute cases. This represents possibly the most serious threat that the global veterinary industry has had to face in the last decades. Serological diagnostic tests, like the Herdscreen¬ģ ASFV Test, are essential tools for the eradication of ASF, as the detection of chronic, subacute or
subclinical infected animals is extremely important to stop the dissemination of the virus in the domestic pig and wild boar populations.

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.

To date, Algenex‚Äô work has centered mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com

About Global DX

Global DX Ltd is a private veterinary diagnostics company developing and producing high quality and innovative diagnostic solutions specialising in Rapid Test technologies. On the basis of more than 70 years of experience in the In Vitro Diagnostics industry, the company is aiming to improve the quality of animal care by facilitating accurate diagnosis for veterinarians worldwide. Building on a range of Rapid Tests for Companion Animals (Petscreen¬ģ) and Livestock Animals (Herdscreen¬ģ) Global DX is applying Rapid Test technologies and novel test solutions for important diseases of worldwide importance.

For more information, please visit Globaldx.com

For further information, please contact:

Algenex contact
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Global DX contact
Andrew Shepherd
Founder & CEO
T: +44 1259 230830
andrew.shepherd@globaldx.com

Science Technology

Algenex obtiene financiación del CDTI para desarrollar productos contra la COVID-19

May 13 2020

La compa√Ī√≠a biotecnol√≥gica espa√Īola Algenex ha conseguido financiaci√≥n del CDTI, dependiente del Ministerio de Ciencia e Innovaci√≥n, para el desarrollo de distintos productos encaminados a luchar contra la actual pandemia de coronavirus. Esta financiaci√≥n permitir√° a la compa√Ī√≠a trabajar en el desarrollo de un candidato de vacuna contra el SARS-CoV-2 y de test diagn√≥sticos para la detecci√≥n de anticuerpos.

Claudia Jim√©nez, Directora General de Algenex, ha se√Īalado que la validaci√≥n del proyecto por el CDTI ‚Äúes una confirmaci√≥n de la madurez de Algenex y de lo prometedora que es nuestra tecnolog√≠a. Ahora que el desarrollo de las vacunas experimentales basadas en prote√≠nas del virus est√° m√°s avanzando, es momento de pensar en c√≥mo garantizar su producci√≥n industrial, considerando tanto el n√ļmero de dosis como su comercializaci√≥n a un precio asumible para que pueda ser usada en campa√Īas de vacunaci√≥n globales. Nuestra tecnolog√≠a CrisBio puede ser fundamental en este aspecto‚ÄĚ, ha se√Īalado.

Tecnología disruptiva y patentada

La compa√Ī√≠a, con sede en la Comunidad de Madrid, cuenta con una tecnolog√≠a disruptiva y patentada para producir productos biotecnol√≥gicos basados en prote√≠nas recombinantes denominada CrisBio¬ģ. CrisBio¬ģ utiliza insectos como biorreactores naturales, mediante la inoculaci√≥n robotizada de virus vectores baculovirus modificados gen√©ticamente, en las cris√°lidas de un lepid√≥ptero, la trichoplusia ni. El virus coloniza las c√©lulas vivas del insecto y √©stas comienzan a producir la prote√≠na deseada.

CrisBio¬ģ permite la producci√≥n de ant√≠genos vacunales, anticuerpos o prote√≠nas diagn√≥sticas de una forma r√°pida y con un escalado industrial lineal y pr√°cticamente ilimitado. Los costes de inversi√≥n en una factor√≠a basada en CrisBio¬ģ, as√≠ como los costes operativos de producci√≥n, son solo una fracci√≥n de aquellos requeridos en factor√≠as tradicionales basadas en biorreactores, permitiendo el acceso global a productos biotecnol√≥gicos.

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Company CrisBio

Algenex advances insect-based vaccine production technology in human health

May 05 2020

Building on its expertise in the production of proteins for veterinary vaccines, Algenex has started to produce biotechnology products for the development of human vaccines and other applications using CrisBio¬ģ, its proprietary and patent protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors.

CrisBio¬ģ is a versatile and robust alternative to current bioreactor-based expression technologies and offers additional benefits including linear scalability, reduced production costs and increased productivity, reaching gram per litre yields.

Algenex has deep expertise in the production of proteins for the production of vaccines for zoonotic diseases that can be transferred to humans. The Company has completed a proof of concept study in avian influenza, a zoonotic disease with potential to turn into a global pandemic. In this study, Algenex demonstrated its ability to develop a fully functional and safe vaccine in only four months, using animal models, an experience upon which it now intends to build to join the fight against pandemics.

Zoonosis

According to Animal Health Europe, more than 2.2 million people die every year from zoonosis, with 75% of new infectious diseases affecting humans coming from animals, such as the recent COVID-19 pandemic.

‚ÄúAlgenex‚Äô CrisBio¬ģ technology is able to produce proteins for vaccines more efficiently, economically and rapidly than current available bioreactor-based expression technologies,‚ÄĚ said Dr. Jos√© Escribano, founder and CSO of Algenex. ‚ÄúAs a result, Algenex is ideally positioned to produce and supply large quantities of proteins to pharmaceutical companies developing and manufacturing vaccines quickly and at competitive prices. This would enable widespread immunization, in particular in countries with weak economies and less advanced public health systems.‚ÄĚ

‚ÄúBy expanding the use of our CrisBio¬ģ technology into human health, we are now able to fully exploit the potential of this platform,‚ÄĚ said Claudia Jim√©nez, General Manager of Algenex. ‚ÄúWith CrisBio we are able to produce a new vector for the development of a potential new vaccine in less than two months. The insects we use as bioreactors are easy to rear in almost unlimited quantities and in a short period of time, allowing almost immediate and unlimited scalability once the parameters for the production have been defined.‚ÄĚ

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com